EN 3285

Drug Profile

EN 3285

Alternative Names: Acetylcysteine oral rinse - Endo; N-acetylcysteine oral rinse - Endo; NAC Oral Rinse; RK 0202

Latest Information Update: 22 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elan Corporation; RxKinetix
  • Developer Endo Pharmaceuticals
  • Class Antibronchitics; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stomatitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Feb 2009 Discontinued - Phase-III for Stomatitis in USA (PO)
  • 08 Feb 2008 Phase-III clinical trials in Stomatitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top